JP2022526764A5 - - Google Patents
Info
- Publication number
- JP2022526764A5 JP2022526764A5 JP2021556753A JP2021556753A JP2022526764A5 JP 2022526764 A5 JP2022526764 A5 JP 2022526764A5 JP 2021556753 A JP2021556753 A JP 2021556753A JP 2021556753 A JP2021556753 A JP 2021556753A JP 2022526764 A5 JP2022526764 A5 JP 2022526764A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antigen
- acid sequence
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024131936A JP2024160318A (ja) | 2019-03-22 | 2024-08-08 | ＥＧＦＲｘＣＤ２８多特異性抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962822124P | 2019-03-22 | 2019-03-22 | |
| US62/822,124 | 2019-03-22 | ||
| PCT/US2020/023857 WO2020198009A1 (en) | 2019-03-22 | 2020-03-20 | EGFR x CD28 MULTISPECIFIC ANTIBODIES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024131936A Division JP2024160318A (ja) | 2019-03-22 | 2024-08-08 | ＥＧＦＲｘＣＤ２８多特異性抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022526764A JP2022526764A (ja) | 2022-05-26 |
| JP2022526764A5 true JP2022526764A5 (enExample) | 2023-03-29 |
| JP7659501B2 JP7659501B2 (ja) | 2025-04-09 |
Family
ID=70228885
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556753A Active JP7659501B2 (ja) | 2019-03-22 | 2020-03-20 | ＥＧＦＲｘＣＤ２８多特異性抗体 |
| JP2024131936A Pending JP2024160318A (ja) | 2019-03-22 | 2024-08-08 | ＥＧＦＲｘＣＤ２８多特異性抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024131936A Pending JP2024160318A (ja) | 2019-03-22 | 2024-08-08 | ＥＧＦＲｘＣＤ２８多特異性抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11912767B2 (enExample) |
| EP (1) | EP3941941A1 (enExample) |
| JP (2) | JP7659501B2 (enExample) |
| KR (1) | KR20210142659A (enExample) |
| CN (1) | CN113661177B (enExample) |
| AU (1) | AU2020247803A1 (enExample) |
| BR (1) | BR112021018442A2 (enExample) |
| CA (1) | CA3134335A1 (enExample) |
| CL (2) | CL2021002446A1 (enExample) |
| CO (1) | CO2021014076A2 (enExample) |
| EA (1) | EA202192566A1 (enExample) |
| IL (1) | IL286536A (enExample) |
| MA (1) | MA55363A (enExample) |
| MX (1) | MX2021011500A (enExample) |
| MY (1) | MY209363A (enExample) |
| PH (1) | PH12021552300A1 (enExample) |
| SG (1) | SG11202110341WA (enExample) |
| WO (1) | WO2020198009A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119143875A (zh) * | 2018-06-21 | 2024-12-17 | 瑞泽恩制药公司 | 双特异性抗psma x抗cd28抗体及其用途 |
| EP3941941A1 (en) | 2019-03-22 | 2022-01-26 | Regeneron Pharmaceuticals, Inc. | Egfr x cd28 multispecific antibodies |
| US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
| WO2022094299A2 (en) * | 2020-10-30 | 2022-05-05 | Janux Therapeutics, Inc. | Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof |
| CN116635425A (zh) * | 2020-11-03 | 2023-08-22 | 德国癌症研究中心公共法律基金会 | 靶细胞限制性、共刺激性、双特异性二价抗cd28抗体 |
| KR20230151513A (ko) | 2021-01-11 | 2023-11-01 | 사나 바이오테크놀로지, 인크. | Cd8 표적 바이러스 벡터의 용도 |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| EP4381081A1 (en) | 2021-08-04 | 2024-06-12 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
| WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| IL314993A (en) | 2022-02-23 | 2024-10-01 | Xencor Inc | Anti-cd28 x anti-psma antibodies |
| EP4490192A1 (en) | 2022-03-07 | 2025-01-15 | Novimmune S.A. | Cd28 bispecific antibodies for targeted t cell activation |
| WO2023174925A1 (en) | 2022-03-14 | 2023-09-21 | Novimmune Sa | Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2023198042A1 (zh) * | 2022-04-11 | 2023-10-19 | 江苏恒瑞医药股份有限公司 | 特异性结合egfr和cd28的抗原结合分子及其医药用途 |
| CN118922449A (zh) * | 2022-04-11 | 2024-11-08 | 江苏恒瑞医药股份有限公司 | 特异性结合psma和cd28的抗原结合分子及其医药用途 |
| KR20250037485A (ko) | 2022-07-13 | 2025-03-17 | 리제너론 파마슈티칼스 인코포레이티드 | 분석물 검출을 위한 약산 면역분석법 |
| US20260027145A1 (en) | 2022-07-27 | 2026-01-29 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| CN120344265A (zh) | 2022-10-03 | 2025-07-18 | 里珍纳龙药品有限公司 | 单独使用双特异性EGFR x CD28抗体或其与抗PD-1抗体组合使用治疗癌症的方法 |
| AU2023362569A1 (en) | 2022-10-21 | 2025-04-24 | Novimmune Sa | Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation |
| WO2024237744A1 (ko) * | 2023-05-18 | 2024-11-21 | 서울대학교산학협력단 | 항-cd40l/항-cd28 이중 특이 항체 및 이의 용도 |
| JP2026524011A (ja) | 2023-07-10 | 2026-07-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 二重特異性ｐｄ－ｌ１×ｃｄ２８抗体およびそれらの使用方法 |
| WO2025026356A1 (zh) * | 2023-07-31 | 2025-02-06 | 百奥泰生物制药股份有限公司 | 靶向肿瘤相关抗原与cd28的双特异性抗体及其应用 |
| CN120647771A (zh) * | 2024-03-15 | 2025-09-16 | 上海鑫湾生物科技有限公司 | 一种激活免疫细胞杀伤肿瘤细胞的融合蛋白及其重组病毒和用途 |
| WO2026078067A1 (en) | 2024-10-08 | 2026-04-16 | Novimmune Sa | Fcrh5 monospecific antibodies and derived fcrh5xcd28 bispecific antibodies and use thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| US7235641B2 (en) * | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8236308B2 (en) | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| SG183149A1 (en) | 2010-02-08 | 2012-09-27 | Regeneron Pharma | Common light chain mouse |
| CN104203981A (zh) | 2011-12-19 | 2014-12-10 | 合成免疫股份有限公司 | 双特异性抗体分子 |
| TWI641619B (zh) * | 2012-06-25 | 2018-11-21 | 美商再生元醫藥公司 | 抗－ｅｇｆｒ抗體及其用途 |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI682941B (zh) * | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| CN104558190B (zh) * | 2015-01-06 | 2018-08-10 | 中国药科大学 | 一种全人源靶向EGFR/KDR的IgG样双特异性抗体 |
| JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| MY195059A (en) | 2015-09-23 | 2023-01-05 | Regeneron Pharma | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof |
| KR102531251B1 (ko) | 2016-09-23 | 2023-05-15 | 리제너론 파아마슈티컬스, 인크. | 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체 |
| KR102520731B1 (ko) | 2016-09-23 | 2023-04-14 | 리제너론 파아마슈티컬스, 인크. | 항-steap2 항체, 항체-약물 컨쥬게이트, 및 steap2 및 cd3에 결합하는 이중특이적 항원-결합 분자, 및 이의 용도 |
| CN106632681B (zh) * | 2016-10-11 | 2017-11-14 | 北京东方百泰生物科技有限公司 | 抗egfr和抗cd3双特异抗体及其应用 |
| KR20210104836A (ko) * | 2018-12-19 | 2021-08-25 | 리제너론 파아마슈티컬스, 인크. | 이중 특이적 항-cd28 x 항-cd22 항체 및 그의 용도 |
| EP3941941A1 (en) | 2019-03-22 | 2022-01-26 | Regeneron Pharmaceuticals, Inc. | Egfr x cd28 multispecific antibodies |
-
2020
- 2020-03-20 EP EP20718108.2A patent/EP3941941A1/en active Pending
- 2020-03-20 CN CN202080022975.8A patent/CN113661177B/zh active Active
- 2020-03-20 MX MX2021011500A patent/MX2021011500A/es unknown
- 2020-03-20 CA CA3134335A patent/CA3134335A1/en active Pending
- 2020-03-20 AU AU2020247803A patent/AU2020247803A1/en active Pending
- 2020-03-20 KR KR1020217032287A patent/KR20210142659A/ko active Pending
- 2020-03-20 PH PH1/2021/552300A patent/PH12021552300A1/en unknown
- 2020-03-20 JP JP2021556753A patent/JP7659501B2/ja active Active
- 2020-03-20 SG SG11202110341WA patent/SG11202110341WA/en unknown
- 2020-03-20 BR BR112021018442A patent/BR112021018442A2/pt unknown
- 2020-03-20 MY MYPI2021005486A patent/MY209363A/en unknown
- 2020-03-20 WO PCT/US2020/023857 patent/WO2020198009A1/en not_active Ceased
- 2020-03-20 MA MA055363A patent/MA55363A/fr unknown
- 2020-03-20 US US16/825,179 patent/US11912767B2/en active Active
- 2020-03-20 EA EA202192566A patent/EA202192566A1/ru unknown
-
2021
- 2021-09-19 IL IL286536A patent/IL286536A/en unknown
- 2021-09-21 CL CL2021002446A patent/CL2021002446A1/es unknown
- 2021-10-21 CO CONC2021/0014076A patent/CO2021014076A2/es unknown
-
2023
- 2023-02-07 US US18/165,515 patent/US12415856B2/en active Active
- 2023-09-21 CL CL2023002805A patent/CL2023002805A1/es unknown
-
2024
- 2024-08-08 JP JP2024131936A patent/JP2024160318A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2560305C (en) | Human anti-epidermal growth factor receptor antibody | |
| JP6518005B2 (ja) | Ｐｄ−ｌ１抗体 | |
| CN103189392B (zh) | ErbB3结合抗体 | |
| JP2020528750A5 (enExample) | ||
| JP2021531764A5 (enExample) | ||
| FI3618863T3 (fi) | Anti-TIGIT-vasta-aineita ja menetelmiä niiden käyttämiseksi | |
| JP2024527606A5 (enExample) | ||
| Ko et al. | Combination of novel HER2‐targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2‐positive gastric cancer | |
| JP2017529838A5 (enExample) | ||
| RU2019104980A (ru) | Анти-icos антитела | |
| JP2023543152A5 (enExample) | ||
| CN114761433B (zh) | 一种抗Claudin18.2单克隆抗体、其制备方法及用途 | |
| TW201920282A (zh) | 抗egfr和pd-1的雙特異性抗體 | |
| JP2024538148A5 (enExample) | ||
| EP3823988A1 (en) | Bispecific antibodies targeting immune checkpoints | |
| WO2018182420A1 (en) | Antibodies for the treatment of erbb-2/erbb-3 positive tumors | |
| JP2024527576A5 (enExample) | ||
| AU2025204836A1 (en) | Combinations of binding moieties that bind EGFR, HER2 and HER3. | |
| CN101233155B (zh) | 人抗表皮生长因子受体抗体 | |
| WO2016163433A1 (ja) | 抗ｆｇｆｒ２抗体と他剤を含む組成物 | |
| HK40080887A (en) | Use of antibody in anti-tumor treatment | |
| JP2026514105A (ja) | 癌の治療のためのｇｒｅｍ１拮抗薬が関与する併用療法 | |
| RU2022107092A (ru) | Новые анти-cldn18.2 антитела | |
| CN120678937A (zh) | 抗nkg2a抗体联合用药的新用途 | |
| RU2025134255A (ru) | Конъюгат антитела к рецептору эпидермального фактора роста (egfr) и лекарственного средства и его применение |